Compare PALI & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PALI | NAGE |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | 117 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.6M | 290.7M |
| IPO Year | 2019 | N/A |
| Metric | PALI | NAGE |
|---|---|---|
| Price | $1.86 | $3.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $11.29 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 3.8M | 893.0K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $260,000.00 | N/A |
| Revenue This Year | N/A | $16.51 |
| Revenue Next Year | N/A | $14.58 |
| P/E Ratio | ★ N/A | $21.29 |
| Revenue Growth | ★ 1500.39 | N/A |
| 52 Week Low | $0.55 | $3.71 |
| 52 Week High | $2.86 | $14.66 |
| Indicator | PALI | NAGE |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 28.37 |
| Support Level | $1.57 | N/A |
| Resistance Level | $1.93 | $5.22 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 19.78 | 2.96 |
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.